about
Republished: Non-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetimeNon-heritable genetics of human disease: spotlight on post-zygotic genetic variation acquired during lifetimeDonor cell-derived leukemias/myelodysplastic neoplasms in allogeneic hematopoietic stem cell transplant recipients: a clinicopathologic study of 10 cases and a comprehensive review of the literature.Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.Bone marrow and karyotype findings of patients with pancytopenia in southern iran.A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome.Influence of Prognostic Factors on OverallSurvival in Myelodysplastic Syndromes.Clinical implications of the quantitative detection of ID4 gene methylation in myelodysplastic syndrome.Cytogenetic profile of Indian patients with de novo myelodysplastic syndromesAge-related somatic structural changes in the nuclear genome of human blood cells.Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signalingPurification of Bone Marrow Clonal Cells from Patients with Myelodysplastic Syndrome via IGF-IR.BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients.H2AX deficiency is associated with erythroid dysplasia and compromised haematopoietic stem cell functionPeculiarities in the Diagnosis Approach of MDS /MPN-U PatientsFavorable outcome of patients who have 13q deletion: a suggestion for revision of the WHO 'MDS-U' designationLenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis.Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L.Changing the treatment paradigm in myelodysplastic syndromes.Update on genetic and molecular markers associated with myelodysplastic syndromes.Prognostic molecular markers in myelodysplastic syndromes.Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.Cytogenetic abnormalities in myelodysplastic syndrome: an overview.Diagnostic challenges in the myelodysplastic syndromes: the current and future role of genetic and immunophenotypic studies.Leukemia diagnosis: today and tomorrow.Immunophenotypic, cytogenetic, and mutational characterization of cell lines derived from myelodysplastic syndrome patients after progression to acute myeloid leukemia.Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome.Acute adrenal insufficiency as a first presentation of myelodysplastic syndrome and sigmoid colon adenocarcinoma: a case report.ETV6 deletion is a common additional abnormality in patients with myelodysplastic syndromes or acute myeloid leukemia and monosomy 7.Morphology, cytogenetics, and survival in myelodysplasia with del(20q) or ider(20q): a multicenter study.Differential diagnosis of myelofibrosis based on WHO 2008 criteria: acute panmyelosis with myelofibrosis, acute megakaryoblastic leukemia with myelofibrosis, primary myelofibrosis and myelodysplastic syndrome with myelofibrosis.Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations.From cryptic chromosomal lesions to pathologically relevant genes: integration of SNP-array with gene expression profiling in myelodysplastic syndrome with normal karyotype.Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.Azacytidine for the treatment of myelodysplastic syndromes in the elderly.Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.Therapy-associated myelodysplastic syndrome with monosomy 7 arising in a Muir-Torre Syndrome patient carrying SETBP1 mutation.
P2860
Q28385687-1B26CB51-927F-42C0-A048-3D7A824711F9Q28392579-AD6E720F-82BD-4603-8E09-9084283B1388Q33394527-C675FA87-486E-44F6-91DE-3EB99E362486Q33707411-B33143F3-DFAA-410E-B7C1-B1A55E9609DEQ33907298-89DDE6A2-6783-4AEC-BAA2-EBD617BF2069Q34065882-C9DD06DD-6717-4CF2-991A-806B870ED564Q34087088-FC0F7524-119F-417C-8DDB-EE75C025674BQ34748960-85AF54FD-7AB0-4AE3-BB9D-11F7173465E7Q35108501-234CFAA8-76D9-4E70-8187-EE62185CA10AQ35611055-91792B6B-54AF-4AB3-A3E1-A47E850A5C22Q35748382-617EBAE1-5ABB-4120-A6E6-3411F8717785Q35803662-A91C0AB3-6C30-40AA-8BF5-359FE0DDFEB5Q35808460-E2130B1D-88E5-49AD-8D2B-A9E083B19046Q36050710-8F296C3D-A0A6-49EB-88CF-FB226B26C464Q36500534-D6995580-B3CF-4689-873F-C0D151AF03FFQ36568877-13624904-8AF8-4F11-A41E-508B85FB6EC8Q36662033-2787CF85-8444-4A79-ADBD-F328FE597DD4Q36832931-AA324C92-50B3-4141-A7B6-F8428E71DB1DQ37005060-2CEE0191-AA51-4169-84BE-F9CA9AC2E3DDQ37277994-2D165DEB-FA10-4901-8B50-E053B0CBB864Q37407161-A6BBB3E2-1714-45DC-BC37-B4A321235673Q37810120-42B9BF6E-9721-4F71-B75F-5F797075E396Q37877204-3434FA79-0015-4732-9715-FAB40A8090F6Q37888830-86E1C394-7674-4CAC-B38F-BA3F8533A658Q38089064-D3BDC18C-44E6-420D-B2F4-7BC3C7BC45CCQ38537725-EA2CB5E8-D6CD-4ACE-85B1-E343552609A9Q38740563-8534A9AC-8C33-4EBC-8C14-06C982D73BE9Q39194154-92138269-1EF4-4E8C-BDA1-1744E7769FCFQ40155470-6F76C810-FBE5-4E96-999F-79543BCE8DC6Q41527689-CCC9C109-4EEC-4DF5-A872-2D068B3ACCDEQ44166914-F20CD078-131B-41A5-B4FB-020E44FF54B3Q44292097-1903DD3D-FD11-4649-810F-B7B54A70E737Q44907228-F82081FE-A284-4785-9DAD-76319E2C0839Q45155324-11FE8001-7CA7-4D58-8BB3-08FF71E2B712Q45405305-A867E68C-C2EF-4A76-9F29-2AF0A594596BQ46330963-E6247699-6A66-40B8-9FB6-01A498CD4B6BQ46606966-21B017AB-E257-4292-8341-296A8062C4DEQ47124670-AFC64804-808D-47B6-9368-11EAEAE2B1A7Q47301676-094A5D51-7CAE-40A1-839C-7BB06DFAC175Q50052553-9A26E41C-1716-4BCC-8ABD-BD6BA59B19AD
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Cytogenetic features in myelodysplastic syndromes
@ast
Cytogenetic features in myelodysplastic syndromes
@en
Cytogenetic features in myelodysplastic syndromes
@nl
type
label
Cytogenetic features in myelodysplastic syndromes
@ast
Cytogenetic features in myelodysplastic syndromes
@en
Cytogenetic features in myelodysplastic syndromes
@nl
prefLabel
Cytogenetic features in myelodysplastic syndromes
@ast
Cytogenetic features in myelodysplastic syndromes
@en
Cytogenetic features in myelodysplastic syndromes
@nl
P2860
P1433
P1476
Cytogenetic features in myelodysplastic syndromes
@en
P2093
Detlef Haase
P2860
P304
P356
10.1007/S00277-008-0483-Y
P407
P577
2008-07-01T00:00:00Z